Research Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Reading of Immune picture in Chronic Myeloid Leukemia in Iraqi Patients


Affiliations
1 Medical Research Unit, College of Medicine, University of Al-Nahrain. Baghdad, Iraq
2 College of Education for Pure Science/Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq
3 College of Basic Education, Mustansiriyah University, Baghdad, Iraq
4 Baghdad Teaching Hospital, Medical City. Baghdad, Iraq
     

   Subscribe/Renew Journal


Chronic myeloid leukemia (CML) is a myeloproliferative disorders characterized by formation of Philadelphia chromosome. After disease development, several events may associate with the reduction of anti-tumor immunity. The present study was designed to investigate the immunological profile of innate and adaptive immune response in Iraqi patients with CML. Patients were grouped into untreated (UT), treated (T) with chemotherapy, while another apparently healthy individuals were recruited to represent the control (C) group. Methods: ELISA technique was used to estimate serum levels of GM-CSF, IL-1α, IL-8, IL2, INF-γ, IL-4, and IL-10 while SRID was used to estimate serum levels of C4, IgM, IgA, and IgG. Results: Regarding to innate immune response, C4 levels significantly reduced in UT and T groups, whereas IL-8increased significantly in UT and T groups. However, there is a non-significant difference in IL-1α and GM-CSF levels. In adaptive immunity, IL-2 in UT and T groups, while IFN-γ levels decreased with high significant difference in both UT and T groups, although non-significant change were noticed in levels of IL-4 and IL-10. Similarly, IgM and IgA concentrations were not affected, with an exception that IgG concentration significantly elevated in treated group. In conclusion, CML disease could modulate the engines of immune response in untreated and during chemotherapy treatment which consequently changes the mechanism of antitumor immunity.

Keywords

CML, Innate Immunity, Adaptive Immunity, GM-CSF, IL-1α, IL-8, INF-γ, IL-2, IL-10, IL4.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Hehlmann R, Hochhaus A. and Baccarrani M. Chronic myeloid leukemia. Lancet. 2007; 370: 342-350.

  • Bennour A, Saad A. and Sennana H. Chronic myeloid leukemia: relevance of cytogenetic and molecular assays. Crit. Rev. Oncol. Hematol. 2016; 97:263-274.

  • World Health Organization. Chronic Myelogenous Leukemia. Available at http://www.who.int/selection_medicines/committees /expert/20/applications/CML.pdf. 2014.

  • Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes J E, Medeiros LJ and Lu G. del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009; 192(1):18-23.

  • Zhang X. and Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998; 92(10):3829-3840.

  • Marley S B. and Gordon M Y. Chronic myeloid leukaemia: stem cell derived but progenitor cell driven. ClinSci (Lond).2005; 109(1):13-25.

  • Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen B T, Gastl G, Baldauf M, Trajanoski Z, Giles f, Hochhaus A, Ernst T, Schenk t, Janssen J J W M, Ossenkoppele G J, Porkka K. and Wolf D. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. J.Clin.Oncol. 2017;35(2):175-184.

  • Rohon P, Porkka K. and Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur. J. Haematol. 2010; 85(5):387-398.

  • Corthay A. Does the immune system naturally protect against cancer? Front Immunol. 2014; 5:197.

  • Shi L, Chen S, Yang L. and Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J. Hematol. Oncol. 2013; 6(1):74.

  • Butte M J, Keir M E, Phamduy T B, Sharpe A H. and Freeman G J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007; 27(1):111-122.

  • Gismondi A, Stabile H, Nisti P. andSantoni A. (2014). Effector functions of natural killer cell subsets in the control of hematological malignancies. Front Immunol. 2014; 6:567.

  • Gantt S, Gervassi A, Jaspan H. and Horton H. The role of myeloid-derived sup-pressor cells in immune ontogeny. Front Immunol. 2014; 5:387.

  • De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De BruyneE, Menu E, Van RietI, Vanderkerken K. and Van Ginderachter J A.Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol. 2014; 4:349.

  • Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A, Barbagallo I, Palumbo G A, Stagno F, Vigneri P. and Di Raimondo F. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One. 2014; 9(7):e101848.

  • Ostrand-Rosenberg S. and Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8):4499–506.

  • Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F. and Bronte V. Hierarchy of immunosuppressive strength among myeloid-derived suppres-sor cell subsets is determined by GM-CSF. Eur J Immunol. 2010; 40(1):22–35.

  • Gabrilovich D I. and Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74.

  • Brimnes MK, Vangsted A J, Knudsen L M, Gimsing P, Gang A O, Johnsen HE. and Svane I M. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA DR(-)/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010; 72(6):540–7.

  • Jitschin R, Braun M, Büttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart MJ, Krause S W, Oefner P J, Le Blanc K, Mackensen A. and Mougiakakos D. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014; 124(5):750–60.

  • Chen C I, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S, Gerss J, Maecker H T, Berdel W E, Juergens H, Lee P P and Rossig C. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2010; 26(3):465–74.

  • Ahmad S M, Svane IM. and Andersen M H. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileuke-mic immunity. Blood Cancer J. 2014; 4:e230.

  • Rodriguez P C, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo M B, Delgado A, Correa P, Brayer J, Sotomayor E M, Antonia S, Ochoa J B. and Ochoa A C. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004; 64(16):5839–49.

  • Srivastava M K, Sinha P, Clements V K, Rodriguez P. and Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010; 70(1):68-77.

  • Lindau D, Gielen P, Kroesen M, Wesseling P. and Adema GJ. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology. 2009; 138(2):105–15.

  • Oberlies J, Watzl C, Giese T, Luckner C, Kropf P, Müller I, Ho A D. and Munder M. Regulation of NK cell function by human granulocyte arginase. J.Immunol. 2009; 182(9):5259-5267.

  • Corzo C A, Cotter M J, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey J C. and Gabrilovich D I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 2009; 182(9):5693-5701.

  • Zahran A M, Badrawy H. and Ibrahim A. Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients. Int. J. Clin. Oncol. 2014; 19(4):753-760.

  • Shi L.; Chen S.; Yang L. and Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J HematolOncol. 2013; 6(1):74.

  • Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y. and Li Y. Upregulated TCRζ Enhances Interleukin-2 Production in T-Cells from Patients with CML. DNA Cell Biol. 2012; 31(11): 1628-1635.

  • Chen S Yang and Chen S Li Y. TCR zeta chain expression in T cells from patients with CML. Hematology, 2009; 14(2):95–100.

  • Humldaová Z, Klamová H, Janatková I, Malíčková K, Králíková P, Šterzl I, Roth Z, Hamšíková E. and Vonka V. Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment. Clin. Dev. Immunol. 2010; 1-17.

  • Shearer WT, Atkinson JP, Frank M M. and Parker CW. Humoralimmuno stimulation IV Role of complement. J. Exp. Med. 1975; 141:736-752.

  • Markiewski M M. and Lambris J D. Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol. 2009; 30:286-292.

  • Ciarcia R, Vitiello M T, Galdiero M, Pacilio C, Iovane V, d'Angelo D, Pagnini D, Caparrotti G, Conti D, Tomei V, Florio S. and Giordano A. Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J. Cell.Physiol. 2012; 227(6):2798-2803.

  • Hantschel O, Gstoettenbauer A, Colinge J, Kaupe I, Bilban M, Burkard T R, Valent P. and Superti-Furga G. The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol. Oncol. 2008; 2(3):272-281.

  • Anand M, Chodda S K, Parikh PM. And Nadkarni J S.Abnormal levels of proinflammatory cytokines in serum and monocyte cultures from patients with chronic myeloid leukemia in different stages, and their role in prognosis. HematolOncol. 1998; 16(4):143-54.

  • Mehta PA, Eapen M, Klein J P, Gandham S Elliott J, Zamzow T, Combs M, Aplenc R, MacMillan M L, Weisdorf D J, Petersdorf E. and Davies SM. Interleukin-1 alpha genotype and outcome of unrelated donor haematopoietic stem cell transplantation for chronic myeloid leukaemia. Br J Haematol. 2007; 137(2):152-7.

  • Held S A, Heine A, Kesper A R, Schönberg K, Beckers A, Wolf D. and Brossart P. Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors. Oncoimmunology. 2016;5(1):e1065368.

  • Held S A E, Bringmann A, Heine A, Kock G, Körber R-M, SeltmannN M.and Brossart P. Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells. Blood. 2010; 116 (issue 21) :3393.

  • Panteli K E, Hatzimichael E C, Bouranta P K, Katsaraki A, Seferiadis K, Stebbing J. andBourantas KL. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005; 130(5):709-15.

  • Pierson B A. and Miller J S. The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma. 1997; 27(5-6):387-399.

  • Liu Y, Kleine H D, Engel H. andAndreeff M. Cytokine expression of T cells in chronic myeloid leukemia. Chin Med J (Engl). 2000; 113(3):232-5.

  • Humlová Z, Klamová H, Janatková I, Malíčková K, Králíková P, Šterzl I, Roth Z, Hamšíková E. and Vonka V. Changes of Immunological Profiles in Patients with Chronic Myeloid Leukemia in the Course of Treatment. Clin. Dev. Immunol. 2010; 1-17.


Abstract Views: 243

PDF Views: 0




  • Reading of Immune picture in Chronic Myeloid Leukemia in Iraqi Patients

Abstract Views: 243  |  PDF Views: 0

Authors

Muhammed A. H. Aldabagh
Medical Research Unit, College of Medicine, University of Al-Nahrain. Baghdad, Iraq
Sahar S. Karieb
College of Education for Pure Science/Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq
Ali N. Yassen
College of Basic Education, Mustansiriyah University, Baghdad, Iraq
Saddam H. Jaber
College of Education for Pure Science/Ibn Al-Haitham, University of Baghdad, Baghdad, Iraq
Mohammed S. Abbas
Baghdad Teaching Hospital, Medical City. Baghdad, Iraq
Ali M. Jawad
Baghdad Teaching Hospital, Medical City. Baghdad, Iraq

Abstract


Chronic myeloid leukemia (CML) is a myeloproliferative disorders characterized by formation of Philadelphia chromosome. After disease development, several events may associate with the reduction of anti-tumor immunity. The present study was designed to investigate the immunological profile of innate and adaptive immune response in Iraqi patients with CML. Patients were grouped into untreated (UT), treated (T) with chemotherapy, while another apparently healthy individuals were recruited to represent the control (C) group. Methods: ELISA technique was used to estimate serum levels of GM-CSF, IL-1α, IL-8, IL2, INF-γ, IL-4, and IL-10 while SRID was used to estimate serum levels of C4, IgM, IgA, and IgG. Results: Regarding to innate immune response, C4 levels significantly reduced in UT and T groups, whereas IL-8increased significantly in UT and T groups. However, there is a non-significant difference in IL-1α and GM-CSF levels. In adaptive immunity, IL-2 in UT and T groups, while IFN-γ levels decreased with high significant difference in both UT and T groups, although non-significant change were noticed in levels of IL-4 and IL-10. Similarly, IgM and IgA concentrations were not affected, with an exception that IgG concentration significantly elevated in treated group. In conclusion, CML disease could modulate the engines of immune response in untreated and during chemotherapy treatment which consequently changes the mechanism of antitumor immunity.

Keywords


CML, Innate Immunity, Adaptive Immunity, GM-CSF, IL-1α, IL-8, INF-γ, IL-2, IL-10, IL4.

References